Industry News

- Read more about Sun Pharma collaborate for research with Israel & Spain
Sun Pharma entered into a tripartite research and option agreement with Israel-based Weizmann Institute of Science and Spain’s Health Research Institute of Santiago de Compostela (IDIS) to develop breakthrough products for the treatment of neurological diseases like brain stroke; as well as glioblastoma, a lethal brain cancer.
- Read more about FDA Advisory Committee Recommends Approval of Teva’s Asthma Biologic Reslizumab
Teva Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee recommended approval of reslizumab, a humanized anti-interleukin-5 (IL-5) IgG4K monoclonal antibody (mAb), in adult patients aged 18 years and older. Reslizumab is a targeted biologic therapy for the treatment of inadequately controlled asthma in patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based treatment regimen.
- Read more about FDA allows marketing of cooling cap to reduce hair loss during chemotherapy
U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss in female breast cancer patients undergoing chemotherapy.
- Read more about Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA Combination Trial
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck’s KEYTRUDA® (pembrolizumab) in a Phase I study across multiple tumor types. Based on the Phase I trial results, the collaboration has the potential to progress to Phase II trials in patients who have been diagnosed with either metastatic breast cancer or non-small cell lung cancer (NSCLC).
- Read more about Sanofi: Dengvaxia®, World's First Dengue Vaccine, Approved in Mexico
Sanofi Pasteur, the vaccines division of Sanofi, announced that the Mexican authorities have granted marketing authorization to Dengvaxia®, making it the first vaccine to be licensed in the world for the prevention of dengue.
- Read more about Malnutrition in India is Declining Faster than before, but not Fast Enough to Meet Global Targets
-Two new reports say urgent action needed to build on new momentum

-The benefit cost ratio of investing in the scaling up nutrition programmes in India is 34 to 1

-India’s stunting “represents the largest loss of human potential in any country in human history
- Read more about NeoBiocon Partners with Novartis to Offer Vildagliptin for Diabetics in UAE
(BWI); NeoBiocon, a collaboration between Asia’s leading biopharmaceuticals company Biocon Ltd and Dr. B.R. Shetty, Chairman of the UAE-based Neopharma, announced today that it has partnered with Novartis Middle East FZE, to market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in UAE. This partnership will help NeoBiocon expand its product offerings in the metabolics segment and will immensely benefit diabetics in UAE.
- Read more about Teva Pharmaceuticals and Eagle Pharmaceuticals got FDA approval of BENDEKA
Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established.

[adsense:336x280:8701650588]
- Read more about Hetero received nod from DCGI for its FDC
Hetero received the approval for the fixed-dose combination (FDC) Ledipasvir-Sofosbuvir (90mg/400mg) from Drug Controller General of India (DCGI). Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Hetero is all set to launch the fixed-dose combination therapy ‘Ledipasvir-Sofosbuvir’ for the Indian patients. The product will be available under the brand name ‘Ledisof’ in India.
- Read more about FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients
U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency. Kanuma is produced by Alexion Pharmaceuticals Inc., based in Cheshire, Connecticut.